Methods of treating schizophrenia and other neuropsychiatric disorders
AssigneesUniversity of Rochester, University of Copenhagen
InventorsSteven A. Goldman, Zhengshan Liu, Mikhail Osipovitch
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of restoring glial cell K+ uptake in a subject. This method involves selecting a subject having impaired glial cell K+ uptake, and administering, to the selected subject, a RE1-Silencing Transcription factor (REST) inhibitor under conditions effective to restore glial cell K+ uptake. Subjects having impaired glial cell K+ uptake include those at risk of having or having a neuropsychiatric disease or disorder.
Claims15
A method of restoring K+ uptake in human glial cells having decreased K+ uptake, said method comprising:
- selecting a population of human glial cells having decreased K+ uptake and
- administering, to the human glial cells having decreased K+ uptake, an inhibitor of RE1-Silencing Transcription factor (REST) selective gene expression under conditions effective to restore K+ uptake by said human glial cells, wherein the inhibitor comprises an inhibitory nucleic acid molecule selected from the group consisting of a REST antisense oligonucleotide, a REST shRNA, and a REST siRNA,
- wherein the inhibitor is packaged in a delivery vehicle that comprises a glial cell targeting moiety.
A method of restoring glial cell K+ uptake in a human subject, said method comprising:
- selecting a human subject having decreased glial cell K+ uptake, and
- administering, to the human subject, an inhibitor of RE1-Silencing Transcription factor (REST) selective gene expression under conditions effective to restore glial cell K+ uptake, wherein the inhibitor comprises an inhibitory nucleic acid molecule selected from the group consisting of a REST antisense oligonucleotide, a REST shRNA, and a REST siRNA,
- wherein the inhibitor is packaged in a delivery vehicle that comprises a glial cell targeting moiety.
A method of treating a neuropsychiatric disorder in a human subject, said method comprising:
- selecting a human subject having decreased glial cell K+ uptake and the neuropsychiatric disorder, and
- administering, to the human subject, an inhibitor of REST selective gene expression under conditions effective to treat the neuropsychiatric disorder in the human subject, wherein the inhibitor comprises an inhibitory nucleic acid molecule selected from the group consisting of a REST antisense oligonucleotide, a REST shRNA, and a REST siRNA, and
- wherein the neuropsychiatric disorder is selected from the group consisting of schizophrenia, autism spectrum disorder, and bipolar disorder.
Dependencies are inferred from the claim text.